From Insight to Action: Tackling the MASLD and MASH Epidemic-Module 3: Screening, Staging, and Monitoring MASLD and MASH

Module 3: Screening, Staging, and Monitoring MASLD and MASH

Video Transcription

Video Summary

This session covers screening, staging, and monitoring Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Key tools include the FIB-4 index for initial fibrosis assessment, followed by Fibroscan for further evaluation, with specific thresholds guiding referrals and monitoring. Advanced diagnostics like MRI-PDFF, MRE, and ELF tests offer detailed assessment but have limitations like cost and availability. Risk stratification targets high-risk groups such as obese and diabetic patients. Monitoring strategies vary by fibrosis stage, emphasizing early detection, lifestyle modification, and specialist care for advanced disease to prevent progression and complications.

Meta Tag

Concept Fatty Liver Disease

Concept Metabolic Dysfunction-Associated Steatohepatitis

Concept FIB-4 Index

Concept Noninvasive Fibrosis Score

Concept FibroScan

Keywords

MASLD

MASH

FIB-4 index

Fibroscan

Risk stratification

Fatty Liver Disease

Metabolic Dysfunction-Associated Steatohepatitis

FIB-4 Index

Noninvasive Fibrosis Score

FibroScan